« Back to Record
Citation APA

Gianni, L., Dafni, U., Gelber, R., de Azambuja, E., Muehlbauer, S., Goldhirsch, A., Untch, M., Smith, I., Baselga, J., Jackisch, C., Cameron, D. A., Mano, M. S., Pedrini, J. L., Veronesi, A., Mendiola, C., Pluzanska, A., Semiglazov, V., Vrdoljak, E., Eckart, M. J., Shen, Z., Skiadopoulos, G., Procter, M., Pritchard, K., Piccart-Gebhart, M., Bell, R. H., & Herceptin Adjuvant (HERA) Trial Study Team, (2011). Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet oncology, 12(3), 236-244. doi:10.1016/S1470-2045(11)70033-X


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/125494

Gianni, L., Dafni, U., Gelber, R., de Azambuja, E., Muehlbauer, S., Goldhirsch, A., Untch, M., Smith, I., Baselga, J., Jackisch, C., Cameron, D. A., Mano, M. S., Pedrini, J. L., Veronesi, A., Mendiola, C., Pluzanska, A., Semiglazov, V., Vrdoljak, E., Eckart, M. J., Shen, Z., Skiadopoulos, G., Procter, M., Pritchard, K., Piccart-Gebhart, M., Bell, R. H., & Herceptin Adjuvant (HERA) Trial Study Team, (2011). Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet oncology, 12(3), 236-244. doi:10.1016/S1470-2045(11)70033-X